πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10046036

Chemically modified cystathionine Ξ²-synthase enzyme for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10040769

HDAC inhibitors for the treatment of diabetic peripheral neuropathy

Regenacy Pharmaceuticals, Inc. Β· Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10039741

Use of delta tocopherol for the treatment of lysosomal storage disorders

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10039738

Ulcer treatment

UNITED ARAB EMIRATES UNIVERSITY Β· Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10034863

Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

PTC THERAPEUTICS, INC. Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10036751

Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment

China Medical University Hospital Β· Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10028939

Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the tre

PTC THERAPEUTICS, INC. Β· Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10022347

Compositions and methods for diagnosis and treatment of metabolic syndrome

United States of America as represented by the Secretary of the Air Force Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10022325

Compositions and methods for the treatment of cancer

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023637

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10016463

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation Β· Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10011589

Treatments for gastrointestinal conditions

The Board of Regents of the University of Texas System Β· Granted Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10004782

Glucokinase activator compositions for the treatment of diabetes

VTV THERAPEUTICS LLC Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10004687

Liposomal curcumin for treatment of diseases

The Board of Regents of the University of Texas System Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10005811

Ξ²-D-2β€²-deoxy-2β€²-Ξ±-fluoro-2β€²Ξ²-C-substituted-2-modified-N6-substituted purine nucleotides fo

Atea Pharmaceuticals, Inc. Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000523

Ξ²-D-2β€²-deoxy-2β€²-Ξ±-fluoro-2β€²-Ξ²-C-substituted-2-modified-N6-substituted purine nucleotides f

Atea Pharmaceuticals, Inc. Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000525

Non-hormonal steroid modulators of NF-ΞΊB for treatment of disease

ReveraGen BioPharma, Inc. Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10000753

Age-related macular degeneration treatment

Benitec Biopharma Limited Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10001483

Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulat

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9994901

Pro-inflammatory mediators in diagnosis and treatment of chronic obstructive pulmonary dis

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9993449

(S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds

Northwestern University Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9993660

Method of using laser-induced optoacoustics for the treatment of drug-resistant microbial

The United States of America as represented by the Secretary of Navy Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9993481

Methods and compositions for the treatment of metabolic disorders

BIOMARIN PHARMACEUTICAL INC. Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9988447

Treatment of diabetes

XBIOTECH INC. Β· Granted Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted